WDB coco Past Earnings Performance
Past criteria checks 4/6
WDB coco has been growing earnings at an average annual rate of 25.3%, while the Life Sciences industry saw earnings growing at 25.6% annually. Revenues have been growing at an average rate of 18.5% per year. WDB coco's return on equity is 24.1%, and it has net margins of 18.7%.
Key information
25.3%
Earnings growth rate
22.9%
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | 18.5% |
| Return on equity | 24.1% |
| Net Margin | 18.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How WDB coco makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 4,595 | 857 | 667 | 0 |
| 31 Dec 23 | 4,385 | 772 | 629 | 0 |
| 30 Sep 23 | 4,251 | 758 | 582 | 0 |
| 30 Jun 23 | 4,188 | 791 | 528 | 0 |
| 31 Mar 23 | 4,070 | 743 | 498 | 0 |
| 31 Dec 22 | 3,994 | 684 | 505 | 0 |
| 30 Sep 22 | 3,853 | 649 | 501 | 0 |
| 30 Jun 22 | 3,779 | 628 | 489 | 0 |
| 31 Mar 22 | 3,615 | 647 | 472 | 0 |
| 31 Dec 21 | 3,363 | 609 | 446 | 0 |
| 30 Sep 21 | 3,116 | 544 | 418 | 0 |
| 30 Jun 21 | 2,776 | 423 | 404 | 0 |
| 31 Mar 21 | 2,570 | 373 | 376 | 0 |
| 31 Dec 20 | 2,460 | 324 | 391 | 0 |
| 30 Sep 20 | 2,346 | 308 | 416 | 0 |
| 30 Jun 20 | 2,277 | 299 | 404 | 0 |
| 31 Mar 20 | 2,285 | 306 | 396 | 0 |
| 31 Mar 19 | 1,781 | 236 | 255 | 0 |
| 31 Mar 18 | 1,466 | 198 | 165 | 0 |
Quality Earnings: 7079 has a high level of non-cash earnings.
Growing Profit Margin: 7079's current net profit margins (18.7%) are higher than last year (18.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7079's earnings have grown significantly by 25.3% per year over the past 5 years.
Accelerating Growth: 7079's earnings growth over the past year (15.3%) is below its 5-year average (25.3% per year).
Earnings vs Industry: 7079 earnings growth over the past year (15.3%) exceeded the Life Sciences industry -18%.
Return on Equity
High ROE: 7079's Return on Equity (24.1%) is considered high.